Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Bioengineering"
DOI: 10.3390/bioengineering8040044
Abstract: Lcn2 overexpression in metastatic breast cancer (MBC) can lead to cancer progression by inducing the epithelial-to-mesenchymal transition and enhancing tumor angiogenesis. In this study, we engineered a PEGylated liposomal system encapsulating lipocalin 2 (Lcn2) small… read more here.
Keywords: pegylated liposomes; lcn2 sirna; breast cancer; metastatic breast ... See more keywords